Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology

Memorial Sloan Kettering Cancer Center. Molecular pathology fellowship. http://www.mskcc.org/education/fellowships/fellowship/molecular-diag-nostics-fellowship. Accessed February 18, 2015.

University of Texas MD Anderson Cancer Center. Molecular genetic pathology fellowship. http://www.mdanderson.org/education-and-research/education-and-training/schools-and-programs/graduate-medical-education/residency-and-fellowship-programs/molecular-genetic-pathology-fellowship.html. Accessed February 18, 2015.

Gonon-Demoulian R. , Goldman J.M. , Nicolini F.E. . History of chronic myeloid leukemia: a paradigm in the treatment of cancer [in French]. Bull Cancer. 2014; 101(1): 56–67.

Gahrton G. . Historical note on the discovery of the Philadelphia chromosome. Cancer Genet. 2012; 205(6): 338–339.

Zhen C. , Wang Y.L. . Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. J Mol Diagn. 2013; 15(5): 556–564.

Leonard D.G. , ed. Molecular Pathology in Clinical Practice: Genetics. New York: Springer; 2008.

Nashed A.L. , Rao K.W. , Gulley M.L. . Clinical applications of BCR-ABL molecular testing in acute leukemia. J Mol Diagn. 2003; 5(2): 63–72.

Pane F. , Frigeri F. , Sindona M. . Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996; 88(7): 2410–2414.

O'Brien S.G. , Guilhot F. , Larson R.A. ; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11): 994–1004.

Branford S. , Fletcher L. , Cross N.C. . Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112(8): 3330–3338.

Press R.D. . Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy. Oncologist. 2010; 15(7): 744–749.

Frankfurt O. , Licht J.D. . Ponatinib–a step forward in overcoming resistance in chronic myeloid leukemia. Clin Cancer Res. 2013; 19(21): 5828–5834.

Gotlib J. , Maxson J.E. , George T.I. . The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013; 122(10): 1707–1711.

Steensma D.P. , Dewald G.W. , Lasho T.L. . The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005; 106(4): 1207–1209.

Elliott M.A. , Hanson C.A. , Dewald G.W. . WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005; 19(2): 313–317.

Maxson J.E. , Gotlib J. , Pollyea D.A. . Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013; 368(19): 1781–1790.

Elliott M.A. , Tefferi A. . Chronic neutrophilic leukemia 2014: update on diagnosis, molecular genetics, and management. Am J Hematol. 2014; 89(6): 651–658.

Baxter E.J. , Scott L.M. , Campbell P.J. ; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464): 1054–1061.

Szpurka H. , Jankowska A.M. , Makishima H. . Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res. 2010; 34(8): 969–973.

Swerdlow E.A. . WHO Classification of Tumours of the Heamatopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008.

Pancrazzi A. , Guglielmelli P. , Ponziani V. . A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008; 10(5): 435–441.

Pikman Y. , Lee B.H. , Mercher T. . MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7): e270.

Ding J. , Komatsu H. , Wakita A. . Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004; 103(11): 4198–4200.

Cankovic M. , Whiteley L. , Hawley R.C. . Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods. Am J Clin Pathol. 2009; 132(5): 713–721.

Steensma D.P. . JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006; 8(4): 397–411.

Cazzola M. , Kralovics R. . From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014; 123(24): 3714–3719.

Klampfl T. , Gisslinger H. , Harutyunyan A.S. . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25): 2379–2390.

Nangalia J. , Massie C.E. , Baxter E.J. . Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25): 2391–2405.

Gangat N. , Caramazza D. , Vaidya R. . DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011; 29(4): 392–397.

Kristensen T. , Vestergaard H. , Møller M.B. . Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011; 13(2): 180–188.

Tefferi A. , Verstovsek S. , Pardanani A. . How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica. 2008; 93(1): 6–9.

Lim K.H. , Tefferi A. , Lasho T.L. . Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009; 113(23): 5727–5736.

Pardanani A. . Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013; 88(7): 612–624.

Gotlib J. . World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol. 2014; 89(3): 325–337.

Cools J. , DeAngelo D.J. , Gotlib J. . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13): 1201–1214.

Bejar R. , Tiu R.V. , Sekeres M.A. . Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges. Am Soc Clin Oncol Educ Book. 2013: e256–e270. http://meetinglibrary.asco.org/sites/meetinglibrary.asco.org/files/Educational%20Book/PDF%20Files/2013/EdBookAM201333e256.pdf. Accessed February 18, 2015.

Jacoby M.A. , Walter M.J. . Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes. Expert Rev Mol Diagn. 2012; 12(3): 253–264.

Lai J.L. , Preudhomme C. , Zandecki M. . Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. Leukemia. 1995; 9(3): 370–381.

Greenberg P. , Cox C. , LeBeau M.M. . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6): 2079–2088.

Schanz J. , Tüchler H. , Solé F. . New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012; 30(8): 820–829.

Malcovati L. , Hellström-Lindberg E. , Bowen D. ; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17): 2943–2964.

Bejar R. . Prognostic models in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2013; 2013: 504–510.

Papaemmanuil E. , Gerstung M. , Malcovati L. ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22): 3616–3627.

Bejar R. , Stevenson K. , Abdel-Wahab O. . Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26): 2496–2506.

Bravo G.M. , Lee E. , Merchan B. . Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. Br J Haematol. 2014; 166(5): 646–659.

Haferlach T. , Nagata Y. , Grossmann V. . Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2): 241–247.

Frampton G.M. , Fichtenholtz A. , Otto G.A. . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11): 1023–1031.

American Cancer Society. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed February 17, 2015.

Nestal de Moraes G. , Castro C.P. , Salustiano E.J. . The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors. Int J Oncol. 2014; 45(5): 1949–1958.

Grimwade D. , Walker H. , Oliver F. ; The Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998; 92(7): 2322–2333.

Slovak M.L. , Kopecky K.J. , Cassileth P.A. . Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000; 96(13): 4075–4083.

Mrózek K. , Marcucci G. , Nicolet D. . Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012; 30(36): 4515–4523.

Döhner H. , Estey E.H. , Amadori S. ; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3): 453–474.

Dufour A. , Schneider F. , Metzeler K.H. . Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010; 28(4): 570–577.

Zeisig B.B. , Kulasekararaj A.G. , Mufti G.J. . SnapShot: acute myeloid leukemia. Cancer Cell. 2012; 22(5): 698–698.e1.

Estey E.H. . Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013; 88(4): 318–327.

Bullinger L. , Döhner K. , Kranz R. . An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood. 2008; 111(9): 4490–4495.

Stirewalt D.L. , Radich J.P. . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9): 650–665.

Tan A.Y. , Westerman D.A. , Carney D.A. . Detection of NPM1 exon 12 mutations and FLT3-internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia. J Hematol Oncol. 2008; 1: 10.

Thiede C. , Creutzig E. , Reinhardt D. . Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia. 2007; 21(2): 366–367.

Lin L.I. , Chen C.Y. , Lin D.T. . Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005; 11(4): 1372–1379.

Leroy H. , Roumier C. , Huyghe P. . CEBPA point mutations in hematological malignancies. Leukemia. 2005; 19(3): 329–334.

Green C.L. , Koo K.K. , Hills R.K. . Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010; 28(16): 2739–2747.

Naoe T. , Kiyoi H. . Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol. 2013; 97(2): 165–174.

Sangle N.A. , Perkins S.L. . Core-binding factor acute myeloid leukemia. Arch Pathol Lab Med. 2011; 135(11): 1504–1509.

Haferlach C. , Bacher U. , Haferlach T. . The inv(3)(q21q26)/t(3;3) (q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia. 2011; 25(5): 874–877.

Rogers H.J. , Vardiman J.W. , Anastasi J. . Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3) (q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014; 99(5): 821–829.

Reis P.P. , Waldron L. , Goswami R.S. . mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol. 2011; 11: 46.

Foundation One. Technical information and test overview. http://foundationone.com/ONE-I-001-20140804_(nobleed)TechnicalSpecs.pdf. Accessed February 25, 2015.

Wang Z.Y. , Chen Z. . Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008; 111(5): 2505–2515.

Cairoli R. , Beghini A. , Grillo G. . Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006; 107(9): 3463–3468.

Moorman A.V. , Chilton L. , Wilkinson J. . A population-based cytogenetic study of adults with acute lymphoblastic leukemia [Erratum appears in Blood. 2010; 116(5): 1017]. Blood. 2010; 115(2): 206–214.

Hoelzer D. , Thiel E. , Löffler H. . Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988; 71(1): 123–131.

Fielding A.K. . How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010; 116(18): 3409–3417.

Hunger S.P. , Lu X. , Devidas M. . Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30(14): 1663–1669.

Hilden J.M. , Dinndorf P.A. , Meerbaum S.O. ; Children's Oncology Group. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006; 108(2): 441–451.

Grimaldi J.C. , Meeker T.C. . The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood. 1989; 73(8): 2081–2085.

Pui C.H. , Relling M.V. , Downing J.R. . Acute lymphoblastic leukemia. N Engl J Med. 2004; 350(15): 1535–1548.

Borowitz M.J. , Hunger S.P. , Carroll A.J. . Predictability of the t(1;19) (q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood. 1993; 82(4): 1086–1091.

Mullighan C.G. . Genome sequencing of lymphoid malignancies. Blood. 2013; 122(24): 3899–3907.

Nachman J.B. , Heerema N.A. , Sather H. . Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007; 110(4): 1112–1115.

Ferrando A.A. , Neuberg D.S. , Dodge R.K. . Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 2004; 363(9408): 535–536.

Turkmen S. , Timmermann B. , Bartels G. . Involvement of the MLL gene in adult T-lymphoblastic leukemia. Genes Chromosomes Cancer. 2012; 51(12): 1114–1124.

Bagg A. . Immunoglobulin and T-cell receptor gene rearrangements: minding your B's and T's in assessing lineage and clonality in neoplastic lymphoproliferative disorders. J Mol Diagn. 2006; 8(4): 426–429.

Sandberg Y. , van Gastel-Mol E.J. , Verhaaf B. . BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J Mol Diagn. 2005; 7(4): 495–503.

Elenitoba-Johnson K.S. , Bohling S.D. , Mitchell R.S. . PCR analysis of the immunoglobulin heavy chain gene in polyclonal processes can yield pseudoclonal bands as an artifact of low B cell number. J Mol Diagn. 2000; 2(2): 92–96.

Nihal M. , Mikkola D. , Wood G.S. . Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin: analysis of the B cell component of the skin-associated lymphoid tissue and implications for the molecular diagnosis of cutaneous B cell lymphomas. J Mol Diagn. 2000; 2(1): 5–10.

Grody W.W. , Nakamura R.M. , Kiechle F.L. . eds. Molecular Diagnostics: Techniques and Applications for the Clinical Laboratory. San Diego, CA: Academic Press; 2010.

Wang S.A. , Wang L. , Hochberg E.P. . Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol. 2005; 29(11): 1490–1496.

Tomita N. . BCL2 and MYC dual-hit lymphoma/leukemia. J Clin Exp Hematop. 2011; 51(1): 7–12.

Swerdlow S.H. . Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DL-BCL and Burkitt lymphoma: when and how, FISH versus IHC. ASH Education Handbook. 2014; (1): 90–99.

Valera A. , Balague O. , Colomo L. . IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010; 34(11): 1686–1694.

Aukema S.M. , Siebert R. , Schuuring E. . Double-hit B-cell lymphomas. Blood. 2011; 117(8): 2319–2331.

Hummel M. , Bentink S. , Berger H. ; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006; 354(23): 2419–2430.

Haralambieva E. , Boerma E.J. , van Imhoff G.W. . Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol. 2005; 29(8): 1086–1094.

Ferry J.A. . Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006; 11(4): 375–383.

Crisan D. , ed. Hematopathology: Genomic Mechanisms of Neoplastic Diseases. New York: Humana Press; 2010.

Sun T. , Nordberg M.L. , Cotelingam J.D. . Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma. Am J Hematol. 2003; 74(1): 78–84.

Seto M. . Cyclin D1-negative mantle cell lymphoma. Blood. 2013; 121(8): 1249–1250.

Dierlamm J. , Baens M. , Wlodarska I. . The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18) (q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999; 93(11): 3601–3609.

Streubel B. , Simonitsch-Klupp I. , Müllauer L. . Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004; 18(10): 1722–1726.

Hamoudi R.A. , Appert A. , Ye H. . Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia. 2010; 24(8): 1487–1497.

Fabbri G. , Rasi S. , Rossi D. . Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011; 208(7): 1389–1401.

Arcaini L. , Zibellini S. , Boveri E. . The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012; 119(1): 188–191.

Tiacci E. , Trifonov V. , Schiavoni G. . BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364(24): 2305–2315.

Tiacci E. , Schiavoni G. , Forconi F. . Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012; 119(1): 192–195.

Treon S.P. , Xu L. , Yang G. . MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med. 2012; 367(9): 826–833.

Treon S.P. , Hunter Z.R. . A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood. 2013; 121(22): 4434–4436.

Murray F. , Darzentas N. , Hadzidimitriou A. . Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008; 111(3): 1524–1533.

Rådestad E. , Wikell H. , Engström M. . Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors. J Immunol Res. 2014; 2014: 578741.

British Committee for Standards in Haematology; Royal College of Pathologists. Best Practice in Lymphoma Diagnosis and Reporting. London: British Society for Haemotology; 2010. http://www.bcshguidelines.com/documents/Lymphoma_diagnosis_bcsh_042010.pdf. Accessed February 18, 2015.

Chitgopeker P. , Sahni D. . T-cell receptor gene rearrangement detection in suspected cases of cutaneous T-cell lymphoma. J Invest Dermatol. 2014; 134(4): e19.

Ioachim H.L. , Medeiros L.J. , eds. Ioachim's Lymph Node Pathology. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009.

Liang X. , Meech S.J. , Odom L.F. . Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol. 2004; 121(4): 496–506.

Rudolph C. , Bittner C. , Feller A.C. . Cytogenetic characteristics of a murine in vitro model for the human anaplastic large cell lymphoma (ALCL). Cytogenet Genome Res. 2006; 114 (3-4): 292–295.

Delgado P. , Starshak P. , Rao N. . A comprehensive update on molecular and cytogenetic abnormalities in T-cell prolymphocytic leukemia (T-pll). J Assoc Genet Technol. 2012; 38(4): 193–198.

Dearden C. . How I treat prolymphocytic leukemia. Blood. 2012; 120(3): 538–551.

Mandava S. , Sonar R. , Ahmad F. . Cytogenetic and molecular characterization of a hepatosplenic T-cell lymphoma: report of a novel chromosomal aberration. Cancer Genet. 2011; 204(2): 103–107.

Tsukasaki K. , Tsushima H. , Yamamura M. . Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood. 1997; 89(3): 948–956.